Every 8-K that Atea Pharmaceuticals, Inc. (AVIR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AVIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVIR filings page.
Atea Pharmaceuticals reported second quarter 2026 results and a major clinical milestone. The Phase 3 C-BEYOND trial of bemnifosbuvir/ruzasvir (BEM/RZR) for hepatitis C met its primary and secondary endpoints in a real-world-like North American population, supporting a potential best-in-class, 8‑week regimen for most non‑cirrhotic patients. A second Phase 3 trial, C-FORWARD, completed enrollment of more than 880 patients across 17 countries, with topline data expected in early Q1 2027 and a potential US NDA submission for BEM/RZR targeted for Q2 2027.
For the quarter ended June 30, 2026, Atea reported a net loss of $32.9 million, compared with $37.2 million a year earlier, as operating expenses declined. Research and development expense was $28.2 million versus $32.3 million, and general and administrative expense was $7.0 million versus $9.1 million, reflecting lower stock-based compensation and professional fees. Cash, cash equivalents and marketable securities were $219.5 million at June 30, 2026, down from $301.8 million at December 31, 2025, with working capital of $200.5 million and no debt-like liabilities indicated.
Atea also initiated a first‑in‑human Phase 1 trial of AT-587 for chronic hepatitis E in immunocompromised patients, addressing an area with no approved antiviral therapies and significant unmet medical need.
Atea Pharmaceuticals reported results from its 2026 annual stockholder meeting. A total of 59,742,819 shares of common stock were represented, about 74.65% of shares outstanding as of the April 24, 2026 record date, indicating strong participation.
Stockholders elected three Class III directors—Jerome Adams, MD, MPH, Howard Berman, PhD, and Barbara Duncan—to serve until the 2029 annual meeting and until their successors are elected and qualified. They also ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved, on an advisory basis, the executive compensation program for the company’s named executive officers.
Atea Pharmaceuticals reported a wider net loss for the first quarter of 2026 as it increased investment in its late-stage antiviral pipeline. Net loss was $45.4 million, or $(0.57) per share, compared with $34.3 million, or $(0.40) per share, a year earlier.
Research and development spending rose to $41.1 million, mainly to fund Phase 3 HCV trials and HEV preclinical work, while general and administrative expenses declined to $6.9 million. Atea ended March 31, 2026 with $256.0 million in cash, cash equivalents and marketable securities.
The company highlighted progress in its hepatitis C program, with Phase 3 C-BEYOND topline results expected in mid-2026 and C-FORWARD results around year-end 2026. It also plans to start a Phase 1 trial of HEV candidate AT-587 in mid-2026.
Atea Pharmaceuticals reported 2025 results showing continued investment in its hepatitis portfolio while narrowing its annual loss. Cash, cash equivalents and marketable securities were $301.8 million as of December 31, 2025, down from $454.7 million a year earlier, reflecting ongoing R&D spending.
For 2025, Atea recorded a net loss of $158.3 million, modestly improved from $168.4 million in 2024, with a basic and diluted net loss per share of $1.94. Research and development expenses were $148.0 million, slightly higher than 2024, driven by its Phase 3 HCV program, while general and administrative expenses declined to $32.9 million due mainly to lower stock-based compensation.
The company advanced its global Phase 3 HCV program for the fixed-dose combination of bemnifosbuvir and ruzasvir, completing enrollment in the North American C-BEYOND trial with over 880 patients and targeting topline results in 2026. It also expanded into hepatitis E with lead candidate AT-587, which is expected to enter clinical development in mid-2026.
Atea Pharmaceuticals, Inc. filed a current report to disclose that it issued a press release with its preliminary unaudited cash and investment balance as of December 31, 2025. The details of this estimated balance are contained in the press release furnished as Exhibit 99.1.
The company emphasizes that this financial information is preliminary, based on currently available data, and remains subject to completion of its fourth-quarter and full-year 2025 financial closing and audit procedures. The information has not been audited or reviewed by its independent registered public accounting firm and is furnished, not filed, meaning it is not subject to certain Exchange Act liability provisions or automatically incorporated into other securities filings.
Atea Pharmaceuticals, Inc. (AVIR) furnished its quarterly earnings press release for the three months ended September 30, 2025. The company reported this under Item 2.02 of Form 8-K on November 12, 2025. The press release is furnished as Exhibit 99.1 and incorporated by reference.
The Item 2.02 information, including Exhibit 99.1, is expressly stated as not deemed “filed” under Section 18 of the Exchange Act and not incorporated into Securities Act or Exchange Act filings unless specifically referenced. The filing also lists Exhibit 104 for the cover page Inline XBRL tags.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) filed an 8-K summarising the results of its 20 June 2025 Annual Meeting of Stockholders.
- Quorum: 74,981,407 shares (≈87.6 % of outstanding) were represented in person or by proxy.
- Director elections (Class II, terms expiring 2028):
- Bruno Lucidi - 46,640,587 FOR / 12,559,084 WITHHOLD / 15,781,736 broker non-votes.
- Polly Murphy, DVM, PhD - 41,184,263 FOR / 18,015,408 WITHHOLD / 15,781,736 broker non-votes.
- Bruce Polsky, MD - 46,597,653 FOR / 12,602,018 WITHHOLD / 15,781,736 broker non-votes.
- Auditor ratification: KPMG LLP re-appointed for FY 2025 with 73,766,274 FOR, 1,192,659 AGAINST, 22,474 ABSTAIN; no broker non-votes.
- Say-on-pay (advisory): 46,450,302 FOR, 12,107,029 AGAINST, 642,340 ABSTAIN, 15,781,736 broker non-votes.
All three proposals passed. No other material business was disclosed in the filing.